Form 8-K

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 3, 2010

 

 

Natus Medical Incorporated

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   000-33001   77-0154833

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

1501 Industrial Road, San Carlos, California 94070

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (650) 802-0400

Not applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

ITEM 5.07. Submission of Matters to a Vote of Security Holders

On June 3, 2010, Natus Medical Incorporated (the “Company”) held its annual meeting of stockholders. At this meeting, James B. Hawkins, President and Chief Executive Officer and Director of the Company, and Robert A. Gunst, Chairman of the Board of Directors, were both re-elected to serve on the Board of Directors for a three-year term until 2013. Additionally, shareholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2010

The number of shares represented in person or in proxy and constituting a quorum was 24,610,037, or approximately 87 % of the Company’s shares outstanding. The results of the shareholder vote are as follows:

Proposal 1: Election of Directors

 

Nominee

   

For

   

Withheld

James B. Hawkins

    16,324,246    5,135,134

Robert A. Gunst

    13,864,530    7,594,850

Proposal 2: Ratification of Deloitte & Touche LLP as Auditors

 

For

   

Against

   

Abstain

24,034,247

    7,982    567,808

No other matters were considered or voted upon at the meeting.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    NATUS MEDICAL INCORPORATED
Date: June 7, 2010     By:  

/s/ Steven J. Murphy

      Steven J. Murphy
      Vice President Finance and Chief Financial Officer